MHA CEO Report — Vaccinations & Respiratory Illness Season

“An ounce of practice is worth more than tons of preaching.” Mahatma Gandhi

The last four years have generated tremendous awareness about vaccines, but also a large public health challenge as disinformation has exploded and anti-vaccine sentiment has emerged from the fringes to become widely embraced. This likely isn’t news to any of you, but the issue is once again top of mind because this time of year is respiratory illness season, whether it be the flu, RSV and now COVID. Thankfully, we have vaccines available to blunt the severe impacts of these illnesses, but it falls on both healthcare providers and public health professionals to appropriately communicate the benefits of vaccines to our patients and the public.

The recent reports from the Centers for Disease Control and Prevention (CDC) are concerning, as they are warning providers about the low vaccination rates for each of these diseases. Flu vaccination rates are down across all age groups compared to last year, while COVID vaccine uptake is the same as last year at just 17% of adults; similarly, only 17% of adults 60 years of age and older have received an RSV vaccine.

Due to these low vaccine rates, the CDC reported Dec. 14 that over the past four weeks, hospitalizations across the country increased 200% for the flu, 51% for COVID and 60% for RSV. In Michigan, we need look no further than last year to see how a surge of RSV illness can dramatically challenge the statewide capacity of our children’s hospitals. We know more can be done and it isn’t too late for people to receive their vaccines that are proven to reduce the risk of severe illness and hospitalization.

The MHA has a long history of support for vaccinations, as we continue to work with the Alliance for Immunizations in Michigan, the Parent Information Network, I Vaccinate and others to measure, educate and promote appropriate vaccinations for all Michigan residents. I Vaccinate specifically has been a terrific statewide public awareness campaign to connect with parents on the value of making sure you keep your children up to date on their vaccinations as they grow up. The bottom line is that the safety and efficacy of numerous vaccines has been supported and documented by not only the CDC, but the World Health Organization, and many other academic and clinical organizations.

We also know healthcare personnel play a key role in limiting the spread of illness during these months. For some time, we have collaborated with the Michigan Department of Health and Human Services to encourage vaccination policies for healthcare personnel against preventable diseases, such as the flu and pertussis.

Healthcare personnel are also important messengers when it comes to vaccines. We highly encourage all patients with questions about vaccines to contact their healthcare provider. These are important decisions and healthcare providers are uniquely qualified to provide accurate information about the benefits and any potential risks associated with any treatment. They also do so with care and respect for their patients. The MHA provides additional vaccine resources to healthcare leaders on our MHA vaccinations webpage.

Since the pandemic, the MHA has engaged in numerous ways on healthcare supply chain issues. On that note, another key challenge has been the available supply of Beyfortus, the monoclonal antibody for infants to prevent severe RSV illness. The MHA has been actively collaborating with stakeholders to navigate these supply concerns, as well as to provide reimbursement clarity. The good news is we have plenty of patients wishing to have their infants immunized, but due to manufacturing and distribution issues, there simply is not enough supply for all these young children. Thankfully the Biden administration recently announced 230,000 additional doses of RSV immunizations for infants will be available this month.

Realistically, we know we won’t change declining vaccination trends overnight, in a society that is as polarized as ever. Yet, I’m hopeful that over time we will be able to turn the tides, much as healthcare providers have for over a hundred years in using this valuable tool to eradicate harmful illnesses. It all starts with individual conversations from trusted messengers, but at the end of the day, we need to practice what we preach.

As always, I welcome your thoughts.

MHA Monday Report Dec. 18, 2023

MHA Monday Report

MDHHS Expands Medicaid Coverage to Include CHW Services

The Michigan Department of Health and Human Services (MDHHS) recently announced an expansion of Medicaid coverage effective Jan. 1, 2024 to include community health worker (CHW) services. The MDHHS also issued a final policy establishing …


Hospital-based Substance Use Disorder Consultation Reimbursement Coverage

Physicians and other qualified practitioners will be reimbursed for substance use disorder (SUD) consultations in the inpatient hospital or emergency department setting effective Jan. 1, 2024. These services include assessment, evaluation, diagnosis and treatment of individuals during …


Coverage of Office-based Substance Use Treatment Services

Primary healthcare providers will be reimbursed for substance use disorder (SUD) treatments that are provided in an office-based primary care setting effective Jan. 1, 2024. This applies to providers who do not have a specialty SUD benefit services contract with a Prepaid .…


Guide and Action Plan Created to Support Health Equity Programming

As strides are made to address inequities and disparities in healthcare, governing and regulatory bodies including The Joint Commission and the Centers for Medicare & Medicaid Services have created guidelines, benchmarks and policies that evolve over time. The MHA Keystone …


Enrollment Deadline Friday for MHA Governance Affinity Group

The deadline to enroll a trustee in the new MHA Governance Affinity Group is Friday, Dec. 22. The benefits of a well-run meeting go beyond parliamentary procedure. Proper communication and facilitation skills needed to make decisions about strategic issues drive performance and .…


Hospital Vaccine Resources Available

The MHA is at the forefront of advocating for vaccination awareness and education, particularly focusing on the challenges associated with the Beyfortus (nirsevimab) monoclonal antibody for infants entering their first respiratory syncytial virus season. The association is …


Latest AHA Trustee Insights Outlines the Board’s Role in Patient Experience

The December edition of Trustee Insights, the monthly digital package from the American Hospital Association (AHA), includes an article on the board’s role in patient experience. The average hospital has turned over 105% of its workforce in the last five years and national …


The Keckley Report

Paul KeckleyThe Affordable Care Act is Back on Stage: What to Expect

“In the last 2 weeks, the Affordable Care Act (ACA) has been inserted itself in Campaign 2024 by Republican aspirants for the White House …

It’s no surprise. Health costs and affordability rank behind the economy as top issues for Republican voters per the latest Kaiser Tracking Poll. And distaste with the status quo is widespread and bipartisan: per the Keckley Poll (October 2023), 70% of Americans including majorities in both parties and age-cohorts under 65 think “the system is fundamentally flawed and needs major change.” To GOP voters, the ACA is to blame. …

The ACA is back on the radar in U.S. healthcare. Stay tuned.”

Paul Keckley, Dec. 10, 2023


News to Know

  • Clarence RuckerClarence Rucker, manager, patient safety and quality, MHA Keystone Center, is featured in COLOR Magazine’s 40 Under 40 Powerlist.
  • Due to the holidays, Monday Report will not be published Dec. 25 and Jan. 1, and will resume its normal schedule Jan. 8.

 


MHA in the News

The MHA received media coverage the week of Dec. 11 related to post-secondary nurse degree programs and telehealth.

Hospital Vaccine Resources Available

The MHA is at the forefront of advocating for vaccination awareness and education, particularly focusing on the challenges associated with the Beyfortus (nirsevimab) monoclonal antibody for infants entering their first respiratory syncytial virus (RSV) season. The association is actively collaborating with stakeholders to navigate reimbursement and supply concerns. A resolution of these issues is being diligently worked towards, with additional manufacturing and distribution channels being explored. Resources on Beyfortus and other vaccinations can be found on the MHA vaccinations webpage.

Additionally, the MHA, in collaboration with the Michigan Department of Health and Human Services, encourages hospitals and health systems to adopt vaccination policies for healthcare personnel against preventable diseases, especially focusing on COVID-19, influenza and pertussis. There are additional resources on the MHA website for hospitals to assess and improve vaccination protocols.

Members with questions may contact Kelsey Ostergren with the MHA.

MHA Monday Report Nov. 6, 2023

MHA Monday Report

capitol buildingHealthcare Worker Protections Headed to Governor

Legislation increasing penalties for violence committed against healthcare workers was approved by the state House of Representatives in a bipartisan vote during the week of Oct. 30. The MHA-supported bills increase fines for assaulting a healthcare …


Michigan Hospitals Invested $784 Million in Community and Voluntary-based Activities to Improve Health, Well-being of Residents

New report outlines hospital community health efforts in FY 2021  The Michigan Health & Hospital Association released today the Making a Difference in Our Communities report that highlights how hospitals invested more than $784 …


Beyfortus Supply Shortages & CDC Guidelines

Beyfortus (nirsevimab) is a long-acting monoclonal antibody for the prevention of respiratory syncytial virus lower respiratory tract disease in infants approved by the U.S. Food and Drug Administration in July 2023. The MHA has …


speak upC.S. Mott Children’s Hospital MRI Technologist Receives Speak-up! Award

The Michigan Health & Hospital Association Keystone Center a Dragan Spremo at University of Michigan Health C.S. Mott Children’s Hospital with the quarterly MHA Keystone Center Speak-up! Award on Oct 23. The MHA Keystone Center …


Registration Open for Virtual DEI Certificate Program

Registration is open for the Diversity, Equity and Inclusion in Healthcare certificate program offered Dec. 7 and Dec. 8 from 11 a.m. to 3 p.m. ET. The event, hosted by the Michigan Health & Hospital …


HHS Submits Information Blocking Disincentives Proposed Rule

The U.S. Department of Health and Human Services (HHS) recently submitted a proposed rule outlining penalties providers would face if they do not appropriately share patient data as outlined in the 21st Century Cures Act. …


MDHHS Launches Opioid Settlement Spending Webpage

The Michigan Department of Health and Human Services (MDHHS) recently published a webpage to track the allocation of $800 million received for opioid settlement investments. MDHHS Chief Medical Executive Dr. Natasha Baghdasarian indicated the website …


MHA Launches New Governance Affinity Group

Hospitals and health systems face significant adversity, yet Michigan providers continue to provide high quality and accessible healthcare to their communities, in great part because of governing boards, executives and staff leadership. Board and committee …


MHA CEO Report — Registration is Representation

As we have discussed in these monthly reports in the past, I am incredibly proud that the MHA is committed to the health equity journey, which once again has been identified by the MHA Board of Trustees as …


The Keckley Report

Paul KeckleySix Majority Beliefs about the U.S. Health System Compromise its Value Proposition

“As news cycles go, this one was standard fare for healthcare: with the exception of business plan announcements by organizations or as elements of tragedies like Lewiston, Gaza or a pandemic, the business of the health system—how it operates is largely uncovered and often subject to misinformation or disinformation. …

In the next 3 weeks, attention will be on the federal budget: healthcare will be in the background unless temporarily an element of a mass tragedy. Each trade group will tout its accomplishments to regulators and pimp their advocacy punch list. Each company will gin-out news releases and commentary about the future of the system will default to think tanks and focused on a single issue of interest.

That’s the problem. In this era of social media, polarization, and mass transparency, these old ways of communicating no longer work. Left unattended, they undermine the value proposition on which the U.S. system is based.”

Paul Keckley, Oct. 30, 2023


News to Know

  • The MHA will host a virtual member from 2 to 3 p.m. on Nov. 9 to outline the MHA 2023 – 2024 strategic action plan approved by the MHA Board of Trustees.
  • The Centers for Medicare and Medicaid Services recently released an updated 2024 Medicare & You Handbook which provides information for patients regarding traditional Medicare, Medicare prescription drug plans, Medicare Advantage and more.

Beyfortus Supply Shortages & CDC Guidelines

Beyfortus (nirsevimab) is a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants approved by the U.S. Food and Drug Administration in July 2023. The MHA has heard significant concerns from members about the cost of purchasing and administering Beyfortus for infants entering their first RSV season since the drug was approved and has been working diligently to alleviate barriers.

The MHA sent letters to Blue Cross Blue Shield of Michigan (BCBSM) and the Michigan Association of Health Plans (MAHP) Oct. 23 to encourage coverage of Beyfortus so cost is not a barrier to adequate protection for the most vulnerable infants. Additionally, the MHA has engaged in conversations with the Michigan Department of Health and Human Services and the Medicaid health plans to confirm Beyfortus is covered through the federally funded Vaccines for Children program. Updates on coverage will be shared as soon as they become available.

The Centers for Disease Control and Prevention (CDC) released a Health Alert Network (HAN) advisory Oct. 23 providing guidance for clinicians in administering Beyfortus given current supply shortages. This follows release of a statement from Sanofi, Beyfortus’ manufacturer, indicating demand for the product has been higher than anticipated and supply has not kept pace, despite an aggressive supply plan.

The CDC’s interim recommendations for prioritizing Beyfortus administration include prioritizing administration of 100mg nirsevimab doses for:

  • Infants younger than six months old.
  • American Indian and Alaska Native infants younger than eight months old.
  • Infants between six to eight months with underlying health conditions that put them at high risk of severe RSV disease.

In addition, children eight to 19 months old should not receive nirsevimab, if they are eligible for palivizumab (Synagis). Lastly, providers should not utilize two, 50mg nirsevimab doses in lieu of one, 100mg dose for infants greater than 11 pounds.

Members may refer to the CDC HAN advisory for the complete recommendation. Members experiencing challenges with billing or reimbursement for Beyfortus administration should contact Kelsey Ostergren at the MHA.